Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant

Clin Vaccine Immunol. 2015 Nov 11;23(1):73-7. doi: 10.1128/CVI.00475-15. Print 2016 Jan.

Abstract

The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to 1 year after vaccination.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adjuvants, Immunologic*
  • Adolescent
  • Adult
  • Antibodies, Viral / blood*
  • Antibodies, Viral / immunology
  • Double-Blind Method
  • Drug Combinations
  • Female
  • Humans
  • Influenza A Virus, H5N1 Subtype / immunology*
  • Influenza Vaccines / administration & dosage
  • Influenza Vaccines / immunology*
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control
  • Male
  • Middle Aged
  • Polysorbates / administration & dosage
  • Squalene / administration & dosage
  • Squalene / immunology*
  • Time Factors
  • Vaccination / adverse effects
  • Young Adult
  • alpha-Tocopherol / administration & dosage
  • alpha-Tocopherol / immunology*

Substances

  • Adjuvants, Immunologic
  • Antibodies, Viral
  • Drug Combinations
  • Influenza Vaccines
  • Polysorbates
  • Squalene
  • AS03 adjuvant
  • alpha-Tocopherol